36C25726N0241↗
Exelan Pharmaceuticals Inc received this contract from 257-Network Contract Office 17 (36C257), Department of Veterans Affairs: $899.3K obligated so far for family & internal medicine services. It runs to 2027-02-05.
Key facts · data as of Oct 23, 2026
- Recipient
- Exelan Pharmaceuticals Inc
- Awarding agency
- Department of Veterans Affairs
- Contracting office
- 257-Network Contract Office 17 (36C257) (36C257)
- Obligated to date
- $899.3K
- Potential value
- $899.3K
- Ends
- 2027-02-05
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 23, 2026.
Cite this page: SpendQuery, Award 36C25726N0241, data as of Oct 23, 2026, https://spendquery.com/award?id=CONT_AWD_36C25726N0241_3600_36F79720D0227_3600
Exelan Pharmaceuticals Inc: all federal awards · Department of Veterans Affairs: spending · 257-Network Contract Office 17 (36C257): what it buys · The follow-on: recompete brief
LENALIDOMIDE ORAL MED
Up for re-bid: ends 2027-02-05. Recompete brief → · 6505--Sources Sought Notice - Ga68 Dotatate (NETSPOT) ↗
What it is
- Product or service
- Family & Internal Medicine Services (PSC Q509)
- Industry
- Pharmaceutical Preparation Manufacturing (NAICS 325412)
- Contracting office
- 257-Network Contract Office 17 (36C257) (36C257)
- Competition
- Full and open competition · 1 offer received
- Pricing
- Firm fixed price
- How it was bought
- GSA Schedule · under 36F79720D0227
- Where the work is
- Palm Beach, FL · district FL-23
Obligations by fiscal year
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
Every action
2 actions since 2026-02-05. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-03-27 | P00001 | Administrative change | $0 | PERIOD OF PERFROMANCE EXTENDED-LENALIDOMIDE ORAL MED |
| 2026-02-05 | 0 | $899.3K | LENALIDOMIDE ORAL MED |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-23). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗